HDFC Mutual Fund Buys a Rs 302 Crore Stake in Molbio Diagnostics as a Motilal Oswal PE Fund Exits
- October 1, 2026
- Posted by: Lakshit Sharma
- Category: News
Molbio Diagnostics Rs 1,313, up 0.3% (1 Oct, 9:13 AM). HDFC MF bought 1.99% for Rs 302.45 crore at Rs 1,315/share from Motilal Oswal PE fund. P/E 91.96 vs industry 66.60.
Quick Answer
The Molbio Diagnostics share price was Rs 1,313 at 9:13 AM on 1 October 2026, up 0.3 percent, after HDFC Mutual Fund acquired 23 lakh shares, a 1.99 percent stake in the Goa-based diagnostics company, for Rs 302.45 crore at Rs 1,315 apiece. Business Excellence Trust III, managed by Motilal Oswal Private Equity, sold 23.28 lakh shares for Rs 306.26 crore at Rs 1,315.01 per share, trimming its stake by 2.02 percentage points. The near-matching size of the buy and sell legs suggests this was a direct transfer between the private equity fund and HDFC Mutual Fund rather than broad market demand. Molbio trades at a P/E of 91.96 against a diagnostics industry average of 66.60, a premium that reflects the company’s position in molecular diagnostics testing.
Molbio Diagnostics Limited, a Goa-based provider of diagnostic solutions known for its molecular testing platforms, saw a notable ownership change on Tuesday. HDFC Mutual Fund acquired 23 lakh shares, equivalent to a 1.99 percent stake, for Rs 302.45 crore at Rs 1,315 per share.
Click Here – Get Free Investment Predictions
On the other side, Business Excellence Trust III, managed by Motilal Oswal Private Equity, pared its stake by 2.02 percentage points, offloading 23.28 lakh shares for Rs 306.26 crore at Rs 1,315.01 per share. This article covers the deal, the company’s valuation, and the risks behind the Molbio Diagnostics share price.
What the HDFC MF Stake Purchase in Molbio Diagnostics Shows
| Item | Detail |
|---|---|
| Buyer | HDFC Mutual Fund |
| Shares bought | 23 lakh (1.99% stake) |
| Value | Rs 302.45 crore |
| Seller | Business Excellence Trust III (Motilal Oswal Private Equity) |
| Shares sold | 23.28 lakh (2.02 percentage points) |
| Value | Rs 306.26 crore |
| Price | Rs 1,315 per share |
A private equity fund trimming its stake years after an initial investment is a routine part of the fund’s own lifecycle, since such funds typically have defined holding periods before returning capital to their own investors. A large public mutual fund like HDFC stepping in to buy at the same price suggests continued institutional confidence in the company rather than a signal of concern.
Also read – Stocks to Watch Today: Alicon Castalloy Jumps 20%, Ircon and Rites Surge on Heavy Volume
Molbio Diagnostics Share Price Today: Numbers and Technical Levels
| Metric | Value (1 Oct, 9:13 AM) |
|---|---|
| Molbio Diagnostics share price | Rs 1,313.00 (up 0.3%) |
| Previous close | Rs 1,308.90 |
| 52-week high / low | Not fully available in the range checked |
| RSI (14-day) | 31.9 |
| SuperTrend | Bullish, support at Rs 1,180.54 |
| 20-day average | Rs 1,269.32 |
| Market cap | Rs 15,090 crore |
| P/E vs industry P/E | 91.96 vs 66.60 |
| Return on equity | 14.25% |
The Molbio Diagnostics share price trades above its 20-day average of Rs 1,269.32, with an RSI of 31.9 that is close to oversold territory despite the stock sitting in a broader uptrend. The SuperTrend indicator remains bullish with support at Rs 1,180.54.
Compare Healthcare and Diagnostics Stocks on the Univest Screener
Valuation Behind the Molbio Diagnostics Share Price
Molbio trades at a P/E of 91.96 against a diagnostics industry average of 66.60, a premium built on the company’s position in molecular point-of-care testing, a segment that saw significant growth since the COVID-19 pandemic. Return on equity of 14.25 percent and debt to equity of 0.38 are reasonable for a growth-stage diagnostics company.
Risks for the Molbio Diagnostics Share Price
Valuation risk is the primary concern, since a P/E nearly 40 percent above the industry average requires sustained growth to justify the premium. Regulatory and reimbursement risk in the diagnostics testing space, where government procurement and health policy can affect demand, is a second factor. Further private equity exits, as holding periods for pre-listing investors continue to run their course, are a third risk that could periodically add supply to the stock.
Download the Univest iOS App or Univest Android App to track the Molbio Diagnostics share price and get alerts on block deals.
Conclusion
The Molbio Diagnostics share price held steady after HDFC Mutual Fund bought a Rs 302 crore stake as a Motilal Oswal private equity fund trimmed its holding at the same price. A bullish technical trend and continued institutional interest are supports, while a valuation premium to the diagnostics industry and the prospect of further private equity exits are risks. Investors deciding whether to buy Molbio Diagnostics shares should watch the Rs 1,269.32 average as support, follow stop-loss levels and consult a SEBI-registered adviser.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Molbio Diagnostics share price today?
Ans. The Molbio Diagnostics share price was Rs 1,313 at 9:13 AM on 1 October 2026, up 0.3 percent from Rs 1,308.90.
Who bought a stake in Molbio Diagnostics?
Ans. HDFC Mutual Fund acquired 23 lakh shares, a 1.99 percent stake, for Rs 302.45 crore at Rs 1,315 per share.
Who sold shares in Molbio Diagnostics?
Ans. Business Excellence Trust III, managed by Motilal Oswal Private Equity, sold 23.28 lakh shares for Rs 306.26 crore, trimming its stake by 2.02 percentage points.
What does Molbio Diagnostics do?
Ans. It is a Goa-based company providing diagnostic solutions, known for its molecular point-of-care testing platforms.
Is the Molbio Diagnostics share price expensive?
Ans. The P/E of 91.96 is well above the diagnostics industry average of 66.60, a premium tied to the company’s position in molecular testing.
What are the key technical levels for the Molbio Diagnostics share price?
Ans. The key levels are SuperTrend support at Rs 1,180.54 and the 20-day average of Rs 1,269.32. The RSI is 31.9.
Why did a private equity fund sell shares in Molbio Diagnostics?
Ans. Private equity funds typically have defined holding periods and return capital to their own investors over time, which is a routine part of their lifecycle rather than necessarily a signal about the company.
Should I buy Molbio Diagnostics shares now?
Ans. Continued institutional buying is a positive sign, but the valuation premium is a risk. Use a stop-loss and consult a SEBI-registered adviser.